Skip to content

PMEI Post-Market Clinical Follow-Up

PMEI Post-Market Clinical Follow-Up

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05565339
Enrollment
497
Registered
2022-10-04
Start date
2020-09-29
Completion date
2023-11-02
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-existing Condition

Keywords

passive middle ear implant

Brief summary

Confirm safety and performance of passive middle ear implants (PMEIs) in subjects with pre-existing condition which made the implantation of a MED-EL PMEI necessary

Detailed description

Collect retrospective audiological and safety results of PMEI implanted subjects. A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated.

Interventions

DEVICEPMEIs

To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed. To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated.

Sponsors

MED-EL Elektromedizinische Geräte GesmbH
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 99 Years

Inclusion criteria

• Inclusion Criteria: Implanted with a MED-EL PMEI; initial implantation or revision implantation receiving a MED-EL PMEI •

Exclusion criteria

None

Design outcomes

Primary

MeasureTime frameDescription
ABGA post-operative minimum and maximum follow-up period was not defined.To collect post-operative PTA4 ABG results. It was expected to achieve a post-operative ABG ≤ 20 dB with a PMEI, by at least 25 % of the total ossicular replacement prostheses patients, by at least 53.8 % of the partial ossicular replacement prostheses patients, and by at least 86 % of the stapes prostheses patients.

Secondary

MeasureTime frameDescription
adverse eventsA post-operative minimum and maximum follow-up period was not defined.To collect device, surgery or procedure related adverse events and bone conduction thresholds

Countries

Austria, Germany, Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026